Faron Pharmaceuticals Oy (AIM:FARN)

Market Cap	67.15M -64.6%
Revenue (ttm)	1.14M
Net Income	-23.78M
EPS	-0.21
Shares Out	115.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	149,151
Average Volume	344,481
Open	52.00
Previous Close	51.00
Day's Range	50.00 - 62.50
52-Week Range	44.00 - 270.00
Beta	1.35
RSI	27.93
Earnings Date	Mar 4, 2026

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 32
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: FARN

Financial Performance

Financial numbers in EUR